Epizyme Presents Pre-Clinical Data And Early Clinical Observations From Ongoing Phase 1 Trial Of EZH2 Inhibitor EPZ-6438 (E7438) At American Society of Hematology Meeting On Lymphoma Biology
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, reported pre-clinical data and early clinical observations from an ongoing Phase 1 trial, being conducted in collaboration with Eisai, the Institut Gustave Roussy, and the Institut Bergonie, of EZH2 inhibitor EPZ-6438 (E7438) in patients with advanced solid tumors and B-cell lymphomas. These data were presented today by Robert Copeland, Ph.D., Chief Scientific Officer, Epizyme, during an oral session on novel therapeutics in lymphoma at the American Society of Hematology (ASH) meeting on Lymphoma Biology, held August 10-13 in Colorado Springs, Colorado. The presentation is available on the Epizyme website at http://www.epizyme.com/?p=1053.
Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. Help employers find you! Check out all the jobs and post your resume.